Chemotherapy resistance is one of the greatest contributors to cancer mortality. A prime example of the impact of our current
inability to overcome treatment resistance is seen in ovarian high grade serous carcinoma (HGSC), which is the most common subtype of epithelial ovarian cancer. While 90% of HGSC patients show no clinically detectable signs of cancer after surgery and chemotherapy, tumors become progressively resistant to chemotherapy leading to five-year survival of <40%. We have established a prospective, longitudinal, multiregion observational study DECIDER (ClinicalTrials.gov identifierNCT04846933) to characterize and overcome chemotherapy resistance in HGSC. In this presentation, I will discuss our latest f
findings on chemotherapy resistance mechanisms in HGSC, derived from comprehensive patient-level data and ex vivo experiments. Specifically, I will focus on highlighting computational methods that facilitate high-quality data collection from patient samples, HGSC tumor evolution before and during chemotherapy, as well as translating research findings to benefit patients.Relevant references for this talk:
Lahtinen A, Lavikka K, Virtanen A, Li Y, Jamalzadeh S, Skorda A, Lauridsen AR, Zhang K, Marchi G, Isoviita VM, Ariotta V, Lehtonen O, Muranen TA, Huhtinen K, Carpén O, Hietanen S, Senkowski W, Kallunki T, Häkkinen A, Hynninen J, Oikkonen J, Hautaniemi S. Evolutionary states and trajectories characterized by distinct pathways stratify patients with ovarian high
Zhang K, Erkan EP, Jamalzadeh S, Dai J, Andersson N, Kaipio K, Lamminen T, Mansuri N, Huhtinen K, Carpén O, Hietanen S,
Oikkonen J, Hynninen J, Virtanen A, Häkkinen A, Hautaniemi S, Vähärautio A. Longitudinal single-cell RNA-seq analysis reveals stress-promoted chemoresistance in metastatic ovarian cancer. Science Advances. 2022 Feb 25;8(8). https://science.org/doi/10.1126/sciadv.abm1831
Häkkinen A, Zhang K, Alkodsi A, Andersson N, Erkan EP, Dai J, Kaipio K, Lamminen T, Mansuri N, Huhtinen K, Vähärautio A, Carpén O, Hynninen J, Hietanen S, Lehtonen R, Hautaniemi S. PRISM: recovering cell-type-specific expression profiles from
individual composite RNA-seq samples. Bioinformatics. 2021 Sep 29;37(18):2882-2888.